Herantis Pharma partners with Indivi to enable detection of early treatment effects in upcoming HER-096 Phase 2 trial in Parkinson’s disease

Herantis Pharma Plc – Press release

• Indivi’s digital biomarker platform is designed to enable earlier and more sensitive detection of treatment-related changes
• Improved sensitivity and reduced variability may support more efficient clinical studies, including shorter study duration and smaller patient cohorts

Espoo, Finland, May 19, 2026: Herantis Pharma Plc ("Herantis"), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, announces a collaboration with Indivi, a Basel-based TechBio company focused on advancing precision medicine in neuroscience drug development, to integrate Indivi’s digital biomarker platform into Herantis’ upcoming Phase 2 proof-of-concept study of HER-096 in people living with Parkinson’s disease.

Indivi’s platform provides functional digital biomarkers derived from smartphone-based assessments of motor and cognitive function, enabling sensitive high-frequency multi-domain disease phenotyping that may support earlier detection of treatment-related changes compared to conventional clinical assessments.

Under the collaboration, Herantis Pharma will incorporate Indivi’s platform alongside conventional clinical assessments in its upcoming double-blind, placebo-controlled, randomized Phase 2 study of HER-096, with the aim of detecting early changes in motor and cognitive function following treatment.

Preparations for the proof-of-concept study are on track and are being further optimized for the integration of Indivi’s digital biomarker platform. Herantis expects to provide additional updates on the Phase 2 trial following completion of the study design.

Antti Vuolanto, CEO of Herantis Pharma, said: “Digital biomarkers have the potential to significantly improve the sensitivity and efficiency of clinical development in Parkinson’s disease. Following an evaluation of available digital health technology solutions, we selected Indivi based on the strength of its scientific capabilities, platform performance, and experience supporting neuroscience clinical studies with leading biotechnology and pharmaceutical companies. We believe the ability to sensitively detect early treatment-related changes in motor and cognitive function may become an important advantage in evaluating the therapeutic potential of HER-096. We are very pleased to collaborate with Indivi and look forward to working together to further strengthen the clinical evaluation of HER-096.”

Schreibe Deinen Kommentar